KRAS mutations are more often associated with heavy smoking, higher tumor mutation burden (TMB), and PD-L1 expression mediated by ERK activation and a high level of tumor-infiltrating lymphocytes (TILs) [23,24]. This evidence concerns the gene KRAS and neoplasm.